•
Apr 30, 2021

Avid Bioservices Q4 2021 Earnings Report

Avid Bioservices reported Q4 2021 financial results, achieving revenue of $27.6 million and annual revenue of $95.9 million. The company signed approximately $148 million in new business orders and achieved a year-end backlog of $118 million.

Key Takeaways

Avid Bioservices reported a strong Q4 and fiscal year 2021, with revenue reaching $27.6 million for the quarter and $95.9 million for the year. The company achieved operational profitability for four consecutive quarters and signed significant new business orders, resulting in a substantial year-end backlog.

Recorded fourth quarter revenue of $27.6 million and annual revenue of $95.9 million.

Achieved four consecutive quarters of operational profitability during fiscal 2021.

Signed approximately $148 million in new business orders and achieved a year-end backlog of $118 million during fiscal 2021.

Project fiscal 2022 revenue of $115 to $117 million, representing 20% - 22% growth over fiscal 2021.

Total Revenue
$27.6M
Previous year: $12.6M
+120.0%
EPS
-$0.04
Previous year: -$0.11
-63.6%
Gross Profit
$8.14M
Previous year: -$1.3M
-726.9%
Cash and Equivalents
$170M
Previous year: $36.3M
+368.6%
Free Cash Flow
$13.7M
Previous year: $2.26M
+506.8%
Total Assets
$266M
Previous year: $108M
+146.7%

Avid Bioservices

Avid Bioservices

Forward Guidance

Avid Bioservices projects fiscal year 2022 revenue between $115 million and $117 million, representing a 20% - 22% increase over fiscal year 2021.